BioGenerics, Inc.
BioGenerics, Inc. is listed today as Coherus Oncology, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2017 | $7 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Sep 2015 | $10 M | Private placement after listing | $10 to $50 million | equity | SEC | |
| May 2014 | $56 M | No. 4 | $50 to $250 million | equity | SEC | |
| Jul 2013 | $28 M | No. 3 | $10 to $50 million | debt, options | SEC | |
| Jan 2012 | $46 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jul 2011 | $13 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Coherus Oncology, Inc., its revenue in fiscal 2025 came from these product and service lines: Toripalimab $40.84 million (97%), Other revenue $1.34 million (3%).
Annual report (SEC XBRL) · Dec 2025
BioGenerics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).
SEC Form D · Dec 2017
The industry group it chose in its notices: Other Health Care.
SEC Form D · Dec 2017
Products and services#
No products or services of BioGenerics, Inc. are on record.
Investors#
15 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Barbara K. Finck | Person | not stated | not stated | Held Series B and C preferred stock (Form 3, 2014) | SEC Form 3 |
| Christos Richards | Person | not stated | not stated | Held Series A, B and C preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Daiichi Sankyo Company, LTD | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Dennis M. Lanfear | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| James Healy | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| KKR Biosimilar GP LLC | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR Biosimilar L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR & Co. L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR Fund Holdings GP Ltd | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR Fund Holdings L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR Group Holdings L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR Group Ltd | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| KKR Management LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lilly Eli & Co | Other | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Lilly Ventures Fund I LLC | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 35 investors.
Largest shareholders today
Institutions holding Coherus Oncology, Inc. shares, as of Sep 30, 2026.
- Timothy G. Youngquist 2020 Irrevocable Trust$16 M8.44%
- BlackRock, Inc.$14 M7.60%
- Vanguard Capital Management LLC$7 M3.62%
- Samsara Biocapital, LLC$4 M2.19%
- Geode Capital Management, LLC$4 M2.01%
- Kohlberg Kravis Roberts & Co. L.P.$4 M1.96%
- State Street Corp$3 M1.57%
- CM Management, LLC$3 M1.36%
- Goldman Sachs Group Inc$2 M1.29%
- C WorldWide Group Holding A/S$2 M1.25%
- ADAR1 Capital Management, LLC$2 M1.22%
- Hudson Bay Capital Management LP$2 M1.12%
- Charles Schwab Investment Management Inc$1 M0.79%
- UBS Group AG$1 M0.67%
- Northern Trust Corp$1 M0.66%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alan C. Herman | Executive officer | Dec 2017 |
| Barbara K. Finck, M.D. | Executive officer | Dec 2017 |
| Dennis M. Lanfear | Executive officer | Dec 2017 |
| Jean Frederic J. Viret, Ph.D. | Executive officer | Dec 2017 |
| Peter K. Watler, Ph.D. | Executive officer | Dec 2017 |
| Barbara K Finck, M.D. | Executive officer | Sep 2015 |
| Jean-Frederic J. Viret, Ph.D. | Executive officer | Sep 2015 |
| George G. Montgomery | Executive officer | Jun 2014 |
| Ali J. Satvat | Director | Dec 2017 |
| August J. Troendle, M.D. | Director | Dec 2017 |
| Christos Bryan Richards | Director | Dec 2017 |
| Dennis M. Lanfear | Director | Dec 2017 |
| James I. Healy, M.D., Ph.D. | Director | Dec 2017 |
| Mary T. Szela | Director | Dec 2017 |
| Mats J. Wahlstrom | Director | Dec 2017 |
| V. Bryan Lawlis | Director | Dec 2017 |
| V. Bryan Lawlis, Ph.D. | Director | Sep 2015 |
| Christos G. Richards | Director | Jun 2014 |
| J. Michael Lazarus, M.D. | Director | Jun 2014 |
| S. Edward Torres | Director | Jun 2014 |
| Christos Michael Richards | Director | Jul 2013 |
| Graham K. Crooke, M.D. | Director | Jul 2013 |
| John Michael Lazarus, M.D. | Director | Jul 2013 |
| Stuart E. Builder, Ph.D. | Director | Jan 2012 |
About
Company in Redwood City, United States.
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.